SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,572,922 | -12.8% | 528,579 | -4.9% | 0.00% | -50.0% |
| Q2 2023 | $16,710,294 | -14.7% | 555,898 | +2.8% | 0.00% | 0.0% |
| Q1 2023 | $19,596,264 | -24.8% | 540,885 | -26.0% | 0.00% | -33.3% |
| Q4 2022 | $26,054,902 | +49.3% | 730,443 | +41.6% | 0.00% | +50.0% |
| Q3 2022 | $17,457,000 | +27.3% | 515,734 | +8.8% | 0.00% | 0.0% |
| Q2 2022 | $13,710,000 | +82.3% | 474,029 | +103.7% | 0.00% | +100.0% |
| Q1 2022 | $7,521,000 | -7.3% | 232,704 | -16.3% | 0.00% | 0.0% |
| Q4 2021 | $8,109,000 | +35.3% | 278,052 | +23.7% | 0.00% | 0.0% |
| Q3 2021 | $5,995,000 | -26.0% | 224,757 | -14.6% | 0.00% | 0.0% |
| Q2 2021 | $8,103,000 | +59.0% | 263,129 | +35.2% | 0.00% | 0.0% |
| Q1 2021 | $5,097,000 | -11.4% | 194,671 | -14.8% | 0.00% | 0.0% |
| Q4 2020 | $5,751,000 | -31.7% | 228,561 | -43.4% | 0.00% | -50.0% |
| Q3 2020 | $8,420,000 | -42.8% | 404,037 | -34.8% | 0.00% | -33.3% |
| Q2 2020 | $14,720,000 | -28.4% | 619,826 | -45.7% | 0.00% | -50.0% |
| Q1 2020 | $20,546,000 | -19.4% | 1,142,109 | +6.3% | 0.01% | 0.0% |
| Q4 2019 | $25,478,000 | +168.4% | 1,074,164 | +211.0% | 0.01% | +100.0% |
| Q3 2019 | $9,492,000 | -10.7% | 345,379 | +7.5% | 0.00% | 0.0% |
| Q2 2019 | $10,632,000 | -22.0% | 321,273 | -17.4% | 0.00% | -25.0% |
| Q1 2019 | $13,636,000 | -23.9% | 389,148 | -27.8% | 0.00% | -20.0% |
| Q4 2018 | $17,912,000 | -8.3% | 539,199 | +39.0% | 0.01% | 0.0% |
| Q3 2018 | $19,524,000 | -31.6% | 387,788 | -18.7% | 0.01% | -37.5% |
| Q2 2018 | $28,537,000 | +192.2% | 476,797 | +123.6% | 0.01% | +166.7% |
| Q1 2018 | $9,766,000 | +8.1% | 213,238 | -6.0% | 0.00% | +50.0% |
| Q4 2017 | $9,036,000 | +3.5% | 226,746 | +3.8% | 0.00% | -33.3% |
| Q3 2017 | $8,733,000 | -50.7% | 218,346 | -46.8% | 0.00% | -40.0% |
| Q2 2017 | $17,702,000 | -19.0% | 410,726 | -41.2% | 0.01% | +66.7% |
| Q1 2017 | $21,864,000 | -15.1% | 698,550 | -31.5% | 0.00% | -25.0% |
| Q4 2016 | $25,746,000 | +212.7% | 1,019,662 | +206.3% | 0.00% | +33.3% |
| Q3 2016 | $8,233,000 | -25.8% | 332,941 | -38.8% | 0.00% | -25.0% |
| Q2 2016 | $11,091,000 | +28.8% | 544,460 | -3.5% | 0.00% | +33.3% |
| Q1 2016 | $8,608,000 | +11.2% | 564,484 | -2.0% | 0.00% | 0.0% |
| Q4 2015 | $7,742,000 | +26.1% | 576,094 | +31.7% | 0.00% | +50.0% |
| Q3 2015 | $6,138,000 | -5.2% | 437,486 | +14.7% | 0.00% | 0.0% |
| Q2 2015 | $6,474,000 | +1307.4% | 381,296 | +902.6% | 0.00% | – |
| Q1 2015 | $460,000 | -70.8% | 38,031 | -79.9% | 0.00% | -100.0% |
| Q4 2014 | $1,573,000 | +231.2% | 189,565 | +247.4% | 0.00% | – |
| Q3 2014 | $475,000 | -41.4% | 54,573 | -26.2% | 0.00% | – |
| Q2 2014 | $810,000 | -70.4% | 73,974 | -75.8% | 0.00% | -100.0% |
| Q1 2014 | $2,735,000 | +146.8% | 305,877 | +108.2% | 0.00% | – |
| Q4 2013 | $1,108,000 | +154.7% | 146,915 | +147.4% | 0.00% | – |
| Q3 2013 | $435,000 | +6.1% | 59,374 | -6.8% | 0.00% | – |
| Q2 2013 | $410,000 | – | 63,713 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |